US Patent

US8242131 — Methods of treating middle-of-the-night insomnia

Method of Use · Assigned to Transcept Pharmaceuticals Inc · Expires 2029-08-20 · 3y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating middle-of-the-night insomnia using low doses of zolpidem or a salt thereof without residual sedative effects.

USPTO Abstract

The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1266 — zolpidem-tartrate
U-1266 — zolpidem-tartrate

Patent Metadata

Patent number
US8242131
Jurisdiction
US
Classification
Method of Use
Expires
2029-08-20
Drug substance claim
No
Drug product claim
No
Assignee
Transcept Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.